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Abstract  
Introduction: Eccrine porocarcinoma (EPC) is a rare tumor. It develops from the intraepidermal ductal portion 
of the eccrine sweat gland. Many chemotherapeutic agents were reported to have efficacy in treatment of 
metastatic EPC; two of very effective agents were docetaxel and 5FU.   
Case Presentation: We are reporting a case of 60 years old female who was diagnosed as metastatic eccrine 
porocarcinoma to mediastinum which was treated by systemic chemotherapy in the form of DCF: docetaxel 75 mg/m2 
D1, cisplatin 75 mg/m2 D1 and continues infusion 5FU 750 mg/m2 from D1 to D4, and this regimen was repeated 
every 28 days for 6 cycles.  
Conclusion: DCF regimen can be one of the best options for stage IV EPC with long overall survival and best response 
rate.  
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Introduction 
Eccrine porocarcinoma EPC of sweat gland is a rare tumor, representing about 0.01% of all 
cutaneous tumors   it is believed to arise from the intra-epithelial portion of eccrine sweat glands, 
first described by Pinkus and Mehregan in 1963 as an uncommon sweat gland carcinoma and the 
malignant counterpart of eccrine poroma [1, 2, 5]. 
Because of the rarity and nonspecific appearance of EPC, a tentative clinical diagnosis will never 
be accurate and the condition might be misdiagnosed as squamous cell carcinoma, basal cell 
carcinoma, seborrheic keratosis, or metastatic adenocarcinoma [5].  
It was previously reported that trunk and abdominal eccrine porocarcinoma presents  - 24% of 
cases [6], in some other reports, the predilection site is the lower extremities (55%), followed by 
the head and scalp (20%), upper limbs (12%), and trunk and abdomen (10%) [7]. 
Many combinations of chemotherapeutic agents were used in eccrine porocarcinoma of sweat gland  
[8, 9], recently one of the most reported effective agent is docetaxel [8]. 
In our case, we used combination of DCF which resulted in radiological complete remission and 
long period of disease free survival and overall survival. 
Case report 
Female patient 60 years old visited Nasser institute adult oncology unit for  post-operative treatment 
after surgery of left groin skin lesion 
  The patient had a history of 11 months of painless left groin skin lesion progressive in size 
associated with surface ulceration The patient was not diabetic or hypertensive, she had no past 
history of chronic  illness. 
 
 
Figure 1 Primary skin lesion 2012 
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Figure 2 Mediastinal lesions before chemotherapy 
 
 Radiological picture: 
CT examination was done for neck, chest, abdomen and pelvis  showing: Figs. 1, 2. The primary 
skin lesion in the form of ulcerative soft tissue mass measuring: 4×9×5 cm at the left groin with 
intact adjacent fat plans and no radiological evidence of  intra-pelvic extension, multiple small 
inguinal lymph nodes were noted. 
Also there was  an enlarged amalgamated mediastinal lymphnodes 10×7.5×7 cm encasing blood 
vessels, with no calcification or lung nodules, The patient underwent surgery; complete excision of 
skin primary only was done on July 2012 under general anesthesia. 
Pathological picture: 
Gross picture of large globular piece of firm, grayish yellow tissue measured 18.0× 10.5× 10.0 cm 
with covered skin ellipse measured 16.0×8.0 cm, outer surface was irregular, multiple and nodular 
masses. Serial cut section was homogenously solid, with multiple variable sized nodules of matted 
lymphoid nodules with friable areas of necrosis. 
Microscopic picture:  
histo-pathological examination of multiple serial section of the spacemen prepared revealed the 
replacement of the tissue by multiple scattered islands of moderately pleomorphic columnar 
looking epithelial cells with poor attempt at acinar formation and no attempts at cell nest formation.  
The cells showing moderate degree of cellular anaplasia, in the form of modest amount of foamy, 
bubbly cytoplasm, large hyper chromatic and pleomorphic nuclei with focally prominent nucleoli.  
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Immunohistochemistry: The tumor cells were strongly positive for CK7, and moderately positive 
for p63. 
The same tumor cell were negative for CK 20, monoclonal CEA and napsin  The final 
histopathological diagnosis was: POROCARCINOMA OF SWEAT GLAND ORIGIN.  
Our final diagnosis was metastatic porocarcinoma of sweat gland to mediastinal lymph node . 
Treatment and follow up: 
1- First line treatment: 
Primary treatment began on august 2012 by chemotherapy: DCF every 28 days for 3 cycles: 
This combination chemotherapy composed of: cisplatin 75 mg/m2 D1, docetaxel 75 mg/m2 D1 and 
5FU 750 mg/m2 D1 to D4 continuous infusion 
After three cycles the patient had radiological partial remission and she continued up to 6 cycles, 
and that was followed by radiological CR (Fig. 3). Then follow up was done every 12 weeks up to 9 
months when the patient presented by new skin lesion 1×1 cm at the end of scar . 
 
 
 
Figure 3 Mediastinal lesion disappeared post DCF chemotherapy 
 
2- Management of local recurrence: 
CT neck, chest, abdomen and pelvis was showing no evidence of distant relapse . Total complete 
excision was done and showing the same histological and clinical picture of the primary.  
  Local recurrence was treated by local radiotherapy after complete excision with safety margins:  
3 DCRT in a dose of 2000cGY 5 fractions in one week. 
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  Positron emmission tomography PET CT was done showing complete remission (Fig. 4). 6 
months later, the patient presented again by second local recurrence and pelvic lymph node 
metastases, 
 
 
Figure 4 PET CT with no metastases post DCF chemotherapy 
 
3- Management of second relapse: 
 There was no radiological evidence of distant metastases during the second relapse and again 
complete  excision was done with lymph node dissection showing the same pathological diagnosi s, 
and she is still on followup till    October 2014. 
Discussion 
EPC is still can be considered a rare tumor, there is no classic guidelines for treatment till now, 
most reported cases were showing different disease courses . 
Large case series by Robson et al. [3] 69 EPC cases reported that local recurrence, lymph node 
metastasis, and distant metastasis were confined to 17, 20, and 10% of the cases, respectively, and 
concluded that aggressive behavior may be the exception, similarly, other authors reported indolent  
biological behavior in EPC [4].  
Our case was presented at the beginning by metastatic mediastinal lymph nodes Figs. 1, 2 which 
appear consistent with the 20% of reported cases.  It was also reported that multi-nodularity, 
ulceration and rapid growth may be associated with local recurrences or metastasis [3], which was 
consistent to the local recurrence that occurred in our case after reaching radiological complete 
remission by systemic chemotherapy. 
Combination chemotherapy regimens using doxorubicin and cyclophospharnide and doxorubicin, 
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cyclophosphamide, and 5-fluorouracil have resulted in two partial responses in carcinoma of sweat 
gland. These responses lasted 8 and 4+ months and occurred in soft tissues and lungs  [9].  
 
Docetaxel was first used for treatment of metastatic sweat gland carcinoma on 2001 by Plunkett et 
al. [8] with good response for three months. 
 In our case we used combination of docetaxel with cisplatin and 5FU continuous infusion which 
resulted in radiological complete remission, Fig. 3, 4 and long period of overall survival and 
disease free survival.  
Our case highlights that DCF regimen is the one of the most effective chemotherapy for systemic 
disease control 9 months and best response rate in the form of radiological complete remission with 
overall survival above 24 months,  
Conclusion 
DCF regimen can be considered as one of the most effective regimens in treatment of metastatic 
porocarcinoma of sweat gland, further investigation and larger studies of EPC should be to put 
guidelines for treatment. 
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